Comparison of Three Treatment Approaches to Decreasing Cardiovascular Disease Risk in Nondiabetic, Insulin Resistant, Dyslipidemic Individuals
暂无分享,去创建一个
C. Lamendola | Yii-Der I. Chen | G. Reaven | H. Farin | F. Abbasi | Y. Chen
[1] C. Lamendola,et al. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. , 2004, Metabolism: clinical and experimental.
[2] B. Nordestgaard,et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.
[3] G. Reaven,et al. Assessment of Insulin Resistance with the Insulin Suppression Test and the Euglycemic Clamp , 1981, Diabetes.
[4] James W. Anderson,et al. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). , 2003, Diabetes care.
[5] Vesa Manninen,et al. Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for Treatment , 1992, Circulation.
[6] R. Krauss,et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? , 2005, The American journal of cardiology.
[7] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[8] G. Reaven,et al. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. , 1970, The Journal of clinical investigation.
[9] T. Wilt,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[10] Margaret Anderson,et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. , 2008, JAMA.
[11] P. Ridker,et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. , 2007, JAMA.
[12] B. Ainsworth,et al. International physical activity questionnaire: 12-country reliability and validity. , 2003, Medicine and science in sports and exercise.
[13] N. Marchionni,et al. Rosiglitazone and cardiovascular risk. , 2007, The New England journal of medicine.
[14] C. Lamendola,et al. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. , 2005, The American journal of cardiology.
[15] G. Reaven,et al. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. , 2000, Diabetes care.
[16] G. Reaven,et al. Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test , 1994, Diabetologia.